These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. Voysey M; Costa Clemens SA; Madhi SA; Weckx LY; Folegatti PM; Aley PK; Angus B; Baillie VL; Barnabas SL; Bhorat QE; Bibi S; Briner C; Cicconi P; Clutterbuck EA; Collins AM; Cutland CL; Darton TC; Dheda K; Dold C; Duncan CJA; Emary KRW; Ewer KJ; Flaxman A; Fairlie L; Faust SN; Feng S; Ferreira DM; Finn A; Galiza E; Goodman AL; Green CM; Green CA; Greenland M; Hill C; Hill HC; Hirsch I; Izu A; Jenkin D; Joe CCD; Kerridge S; Koen A; Kwatra G; Lazarus R; Libri V; Lillie PJ; Marchevsky NG; Marshall RP; Mendes AVA; Milan EP; Minassian AM; McGregor A; Mujadidi YF; Nana A; Padayachee SD; Phillips DJ; Pittella A; Plested E; Pollock KM; Ramasamy MN; Ritchie AJ; Robinson H; Schwarzbold AV; Smith A; Song R; Snape MD; Sprinz E; Sutherland RK; Thomson EC; Török ME; Toshner M; Turner DPJ; Vekemans J; Villafana TL; White T; Williams CJ; Douglas AD; Hill AVS; Lambe T; Gilbert SC; Pollard AJ; Lancet; 2021 Mar; 397(10277):881-891. PubMed ID: 33617777 [TBL] [Abstract][Full Text] [Related]
23. Antibody response after first and second-dose of ChAdOx1-nCOV (Covishield Singh AK; Phatak SR; Singh R; Bhattacharjee K; Singh NK; Gupta A; Sharma A Vaccine; 2021 Oct; 39(44):6492-6509. PubMed ID: 34600747 [TBL] [Abstract][Full Text] [Related]
24. Adverse Events Following COVID-19 Vaccination in Selected Apartments in Bangalore, India. Chakraborty A; Reval N; Kamath L Cureus; 2022 Feb; 14(2):e21809. PubMed ID: 35291520 [TBL] [Abstract][Full Text] [Related]
25. A prospective observational safety study on ChAdOx1 nCoV-19 corona virus vaccine (recombinant) use in healthcare workers- first results from India. Kaur U; Ojha B; Pathak BK; Singh A; Giri KR; Singh A; Das A; Misra A; Yadav AK; Kansal S; Chakrabarti SS EClinicalMedicine; 2021 Aug; 38():101038. PubMed ID: 34505032 [TBL] [Abstract][Full Text] [Related]
26. Long-Term Safety Analysis of the ChAdOx1-nCoV-19 Corona Virus Vaccine: Results from a Prospective Observational Study in Priority Vaccinated Groups in North India. Kaur U; Fatima Z; Maheshwari K; Sahni V; Dehade A; Kl A; Yadav AK; Kansal S; Jaisawal V; Chakrabarti SS Drug Saf; 2023 Jun; 46(6):553-563. PubMed ID: 37133805 [TBL] [Abstract][Full Text] [Related]
27. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. Ramasamy MN; Minassian AM; Ewer KJ; Flaxman AL; Folegatti PM; Owens DR; Voysey M; Aley PK; Angus B; Babbage G; Belij-Rammerstorfer S; Berry L; Bibi S; Bittaye M; Cathie K; Chappell H; Charlton S; Cicconi P; Clutterbuck EA; Colin-Jones R; Dold C; Emary KRW; Fedosyuk S; Fuskova M; Gbesemete D; Green C; Hallis B; Hou MM; Jenkin D; Joe CCD; Kelly EJ; Kerridge S; Lawrie AM; Lelliott A; Lwin MN; Makinson R; Marchevsky NG; Mujadidi Y; Munro APS; Pacurar M; Plested E; Rand J; Rawlinson T; Rhead S; Robinson H; Ritchie AJ; Ross-Russell AL; Saich S; Singh N; Smith CC; Snape MD; Song R; Tarrant R; Themistocleous Y; Thomas KM; Villafana TL; Warren SC; Watson MEE; Douglas AD; Hill AVS; Lambe T; Gilbert SC; Faust SN; Pollard AJ; Lancet; 2021 Dec; 396(10267):1979-1993. PubMed ID: 33220855 [TBL] [Abstract][Full Text] [Related]
28. Analysis of Adverse Effects of COVID-19 Vaccines Experienced by Healthcare Workers at Guizhou Provincial Staff Hospital, China. Wei Y; Wang Y; Liu L; Zha Y; Yang Y; Wang Y; Roberts N; Li Y Vaccines (Basel); 2022 Sep; 10(9):. PubMed ID: 36146526 [TBL] [Abstract][Full Text] [Related]
29. Adverse events following immunization of COVID-19 (Covaxin) vaccine at a tertiary care center of India. Parida SP; Sahu DP; Singh AK; Alekhya G; Subba SH; Mishra A; Padhy BM; Patro BK J Med Virol; 2022 Jun; 94(6):2453-2459. PubMed ID: 35149993 [TBL] [Abstract][Full Text] [Related]
30. Superficial venous thrombosisas a possible consequence of ChAdOx1 nCoV-19 vaccine: two case reports. Sah MK; Singh BM; Sinha P; Devkota P; Yadav SK; Shrestha J; Shrestha A J Med Case Rep; 2022 May; 16(1):182. PubMed ID: 35524323 [TBL] [Abstract][Full Text] [Related]
31. Adverse events following immunization of COVID-19 vaccine among children aged 6-11 years. Puspitarani F; Sitaresmi MN; Ahmad RA Front Public Health; 2022; 10():999354. PubMed ID: 36388348 [TBL] [Abstract][Full Text] [Related]
32. Adverse Events Following Immunization Associated with the First and Second Doses of the ChAdOx1 nCoV-19 Vaccine among Healthcare Workers in Korea. Jeon M; Kim J; Oh CE; Lee JY Vaccines (Basel); 2021 Sep; 9(10):. PubMed ID: 34696204 [TBL] [Abstract][Full Text] [Related]
33. Central nervous system adverse events after ChAdOx1 vaccination. Maramattom BV; Lotlikar RS; Sukumaran S Neurol Sci; 2022 Jun; 43(6):3503-3507. PubMed ID: 35275317 [TBL] [Abstract][Full Text] [Related]
34. Adverse events following immunization (AEFI): COVID-19 vaccine dose and characteristics in Central Java, Indonesia. Wahyudi F; Nugraheni A; Margawati A; Pramono D; Adespin DA; Nugroho TW; Pramana C Germs; 2023 Mar; 13(1):40-49. PubMed ID: 38023961 [TBL] [Abstract][Full Text] [Related]
35. Prevalence of severe adverse events among health professionals after receiving the first dose of the ChAdOx1 nCoV-19 coronavirus vaccine (Covishield) in Togo, March 2021. Konu YR; Gbeasor-Komlanvi FA; Yerima M; Sadio AJ; Tchankoni MK; Zida-Compaore WIC; Nayo-Apetsianyi J; Afanvi KA; Agoro S; Salou M; Landoh DE; Nyansa AB; Boko E; Mijiyawa M; Ekouevi DK Arch Public Health; 2021 Nov; 79(1):207. PubMed ID: 34819146 [TBL] [Abstract][Full Text] [Related]
36. Risk of Repeated Adverse Effects following Booster Dose of mRNA COVID-19 Vaccine: Results from the MOSAICO Study. Ferrara P; Ponticelli D; Losa L; Romeo C; Magliuolo R; Vitale A; Zampella A; Alleanza L; Borrelli M; Schiavone B; Mantovani LG Vaccines (Basel); 2023 Jan; 11(2):. PubMed ID: 36851125 [TBL] [Abstract][Full Text] [Related]
37. Surveillance of Adverse Events Following Immunization (AEFI) after Third Dose Booster Vaccination with mRNA-Based Vaccine in Universitas Indonesia Hospital Health Personnel. Hidayat R; Mustika AP; Avisha F; Djuliannisaa Z; Winari DD; Putri RA; Lisman HM; Davin V; Widhani A; Aini MH; Rahmadani M; Istanti ND; Giantini A Vaccines (Basel); 2022 May; 10(6):. PubMed ID: 35746485 [TBL] [Abstract][Full Text] [Related]
38. Adverse effects after first and second dose of covishield and covaxin: A longitudinal study. Mittal A; Jain B; Varshney AM; Garg G; Sachan D; Singh RB J Family Med Prim Care; 2022 Nov; 11(11):7339-7345. PubMed ID: 36993127 [TBL] [Abstract][Full Text] [Related]
39. Assessment of safety and adverse events following COVID-19 vaccination and their predictors in first 30 days among healthcare workers of a tertiary care teaching hospital in North India. Bashar MA; Kamble B; Kumar S; Nandekar SV; Mathur SK Vaccine X; 2024 Aug; 19():100522. PubMed ID: 39077369 [TBL] [Abstract][Full Text] [Related]
40. Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine in children aged 6-17 years: a preliminary report of COV006, a phase 2 single-blind, randomised, controlled trial. Li G; Cappuccini F; Marchevsky NG; Aley PK; Aley R; Anslow R; Bibi S; Cathie K; Clutterbuck E; Faust SN; Feng S; Heath PT; Kerridge S; Lelliott A; Mujadidi Y; Ng KF; Rhead S; Roberts H; Robinson H; Roderick MR; Singh N; Smith D; Snape MD; Song R; Tang K; Yao A; Liu X; Lambe T; Pollard AJ; Lancet; 2022 Jun; 399(10342):2212-2225. PubMed ID: 35691324 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]